{"product_id":"a-practical-guide-to-designing-phase-ii-trials-in-oncology-isbn-9781118570906","title":"A Practical Guide to Designing Phase II Trials in Oncology","description":"\u003cp\u003e\u003cb\u003eHow to identify optimal phase II trial designs\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eProviding a practical guide containing the information needed to make crucial decisions regarding phase II trial designs, \u003ci\u003eA Practical Guide to Designing Phase II Trials in Oncology\u003c\/i\u003e sets forth specific points for consideration between the statistician and clinician when designing a phase II trial, including issues such as how the treatment works, choice of outcome measure and randomization, and considering both academic and industry perspectives. A comprehensive and systematic library of available phase II trial designs is included, saving time otherwise spent considering multiple manuscripts, and real-life practical examples of using this approach to design phase II trials in cancer are given.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eA Practical Guide to Designing Phase II Trials in Oncology\u003c\/i\u003e:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eOffers a structured and practical approach to phase II trial design\u003c\/li\u003e \u003cli\u003eConsiders trial design from both an academic and industry perspective\u003c\/li\u003e \u003cli\u003eIncludes a structured library of available phase II trial designs\u003c\/li\u003e \u003cli\u003eIs relevant to both clinical and statistical researchers at all levels\u003c\/li\u003e \u003cli\u003eIncludes real life examples of applying this approach\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eFor those new to trial design, \u003ci\u003eA Practical Guide to Designing Phase II Trials in Oncology\u003c\/i\u003e will be a unique and practical learning tool, providing an introduction to the concepts behind informed decision making in phase II trials. For more experienced practitioners, the book will offer an overview of new, less familiar approaches to phase II trial design, providing alternative options to those which they may have previously used.\u003c\/p\u003e \u003cp\u003eContributors xv\u003c\/p\u003e \u003cp\u003eForeword I xvii\u003cbr\u003e \u003ci\u003eElizabeth A. Eisenhauer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eForeword II xix\u003cbr\u003e \u003ci\u003eRoger A’Hern\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePreface xxi\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Introduction 1\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSarah Brown, Julia Brown, Walter Gregory and Chris Twelves\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1.1 The role of phase II trials in cancer 3\u003c\/p\u003e \u003cp\u003e1.2 The importance of appropriate phase II trial design 5\u003c\/p\u003e \u003cp\u003e1.3 Current use of phase II designs 6\u003c\/p\u003e \u003cp\u003e1.4 Identifying appropriate phase II trial designs 7\u003c\/p\u003e \u003cp\u003e1.5 Potential trial designs 9\u003c\/p\u003e \u003cp\u003e1.6 Using the guidance to design your trial 10\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Key Points for Consideration 12\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSarah Brown, Julia Brown, Marc Buyse, Walter Gregory, Mahesh Parmar and Chris Twelves\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2.1 Stage 1 – Trial questions 14\u003c\/p\u003e \u003cp\u003e2.1.1 Therapeutic considerations 14\u003c\/p\u003e \u003cp\u003e2.1.2 Primary intention of trial 16\u003c\/p\u003e \u003cp\u003e2.1.3 Number of experimental treatment arms 17\u003c\/p\u003e \u003cp\u003e2.1.4 Primary outcome of interest 18\u003c\/p\u003e \u003cp\u003e2.2 Stage 2 – Design components 18\u003c\/p\u003e \u003cp\u003e2.2.1 Outcome measure and distribution 18\u003c\/p\u003e \u003cp\u003e2.2.2 Randomisation 21\u003c\/p\u003e \u003cp\u003e2.2.3 Design category 26\u003c\/p\u003e \u003cp\u003e2.3 Stage 3 – Practicalities 33\u003c\/p\u003e \u003cp\u003e2.3.1 Practical considerations 33\u003c\/p\u003e \u003cp\u003e2.4 Summary 35\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Designs for Single Experimental Therapies with a Single Arm 36\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSarah Brown\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3.1 One-stage designs 36\u003c\/p\u003e \u003cp\u003e3.1.1 Binary outcome measure 36\u003c\/p\u003e \u003cp\u003e3.1.2 Continuous outcome measure 38\u003c\/p\u003e \u003cp\u003e3.1.3 Multinomial outcome measure 39\u003c\/p\u003e \u003cp\u003e3.1.4 Time-to-event outcome measure 40\u003c\/p\u003e \u003cp\u003e3.1.5 Ratio of times to progression 40\u003c\/p\u003e \u003cp\u003e3.2 Two-stage designs 41\u003c\/p\u003e \u003cp\u003e3.2.1 Binary outcome measure 41\u003c\/p\u003e \u003cp\u003e3.2.2 Continuous outcome measure 50\u003c\/p\u003e \u003cp\u003e3.2.3 Multinomial outcome measure 50\u003c\/p\u003e \u003cp\u003e3.2.4 Time-to-event outcome measure 53\u003c\/p\u003e \u003cp\u003e3.2.5 Ratio of times to progression 54\u003c\/p\u003e \u003cp\u003e3.3 Multi-stage designs 55\u003c\/p\u003e \u003cp\u003e3.3.1 Binary outcome measure 55\u003c\/p\u003e \u003cp\u003e3.3.2 Continuous outcome measure 59\u003c\/p\u003e \u003cp\u003e3.3.3 Multinomial outcome measure 59\u003c\/p\u003e \u003cp\u003e3.3.4 Time-to-event outcome measure 60\u003c\/p\u003e \u003cp\u003e3.3.5 Ratio of times to progression 60\u003c\/p\u003e \u003cp\u003e3.4 Continuous monitoring designs 60\u003c\/p\u003e \u003cp\u003e3.4.1 Binary outcome measure 60\u003c\/p\u003e \u003cp\u003e3.4.2 Continuous outcome measure 63\u003c\/p\u003e \u003cp\u003e3.4.3 Multinomial outcome measure 63\u003c\/p\u003e \u003cp\u003e3.4.4 Time-to-event outcome measure 63\u003c\/p\u003e \u003cp\u003e3.4.5 Ratio of times to progression 64\u003c\/p\u003e \u003cp\u003e3.5 Decision-theoretic designs 64\u003c\/p\u003e \u003cp\u003e3.5.1 Binary outcome measure 64\u003c\/p\u003e \u003cp\u003e3.5.2 Continuous outcome measure 65\u003c\/p\u003e \u003cp\u003e3.5.3 Multinomial outcome measure 65\u003c\/p\u003e \u003cp\u003e3.5.4 Time-to-event outcome measure 65\u003c\/p\u003e \u003cp\u003e3.5.5 Ratio of times to progression 65\u003c\/p\u003e \u003cp\u003e3.6 Three-outcome designs 65\u003c\/p\u003e \u003cp\u003e3.6.1 Binary outcome measure 65\u003c\/p\u003e \u003cp\u003e3.6.2 Continuous outcome measure 66\u003c\/p\u003e \u003cp\u003e3.6.3 Multinomial outcome measure 66\u003c\/p\u003e \u003cp\u003e3.6.4 Time-to-event outcome measure 66\u003c\/p\u003e \u003cp\u003e3.6.5 Ratio of times to progression 67\u003c\/p\u003e \u003cp\u003e3.7 Phase II\/III designs 67\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 Designs for Single Experimental Therapies Including Randomisation 68\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSarah Brown\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4.1 One-stage designs 68\u003c\/p\u003e \u003cp\u003e4.1.1 Binary outcome measure 68\u003c\/p\u003e \u003cp\u003e4.1.2 Continuous outcome measure 70\u003c\/p\u003e \u003cp\u003e4.1.3 Multinomial outcome measure 70\u003c\/p\u003e \u003cp\u003e4.1.4 Time-to-event outcome measure 70\u003c\/p\u003e \u003cp\u003e4.1.5 Ratio of times to progression 72\u003c\/p\u003e \u003cp\u003e4.2 Two-stage designs 72\u003c\/p\u003e \u003cp\u003e4.2.1 Binary outcome measure 72\u003c\/p\u003e \u003cp\u003e4.2.2 Continuous outcome measure 73\u003c\/p\u003e \u003cp\u003e4.2.3 Multinomial outcome measure 74\u003c\/p\u003e \u003cp\u003e4.2.4 Time-to-event outcome measure 75\u003c\/p\u003e \u003cp\u003e4.2.5 Ratio of times to progression 75\u003c\/p\u003e \u003cp\u003e4.3 Multi-stage designs 75\u003c\/p\u003e \u003cp\u003e4.3.1 Binary outcome measure 75\u003c\/p\u003e \u003cp\u003e4.3.2 Continuous outcome measure 75\u003c\/p\u003e \u003cp\u003e4.3.3 Multinomial outcome measure 75\u003c\/p\u003e \u003cp\u003e4.3.4 Time-to-event outcome measure 76\u003c\/p\u003e \u003cp\u003e4.3.5 Ratio of times to progression 76\u003c\/p\u003e \u003cp\u003e4.4 Continuous monitoring designs 76\u003c\/p\u003e \u003cp\u003e4.4.1 Binary outcome measure 76\u003c\/p\u003e \u003cp\u003e4.4.2 Continuous outcome measure 76\u003c\/p\u003e \u003cp\u003e4.4.3 Multinomial outcome measure 76\u003c\/p\u003e \u003cp\u003e4.4.4 Time-to-event outcome measure 76\u003c\/p\u003e \u003cp\u003e4.4.5 Ratio of times to progression 76\u003c\/p\u003e \u003cp\u003e4.5 Three-outcome designs 77\u003c\/p\u003e \u003cp\u003e4.5.1 Binary outcome measure 77\u003c\/p\u003e \u003cp\u003e4.5.2 Continuous outcome measure 77\u003c\/p\u003e \u003cp\u003e4.5.3 Multinomial outcome measure 77\u003c\/p\u003e \u003cp\u003e4.5.4 Time-to-event outcome measure 77\u003c\/p\u003e \u003cp\u003e4.5.5 Ratio of times to progression 77\u003c\/p\u003e \u003cp\u003e4.6 Phase II\/III designs 77\u003c\/p\u003e \u003cp\u003e4.6.1 Binary outcome measure 77\u003c\/p\u003e \u003cp\u003e4.6.2 Continuous outcome measure 79\u003c\/p\u003e \u003cp\u003e4.6.3 Multinomial outcome measure 80\u003c\/p\u003e \u003cp\u003e4.6.4 Time-to-event outcome measure 81\u003c\/p\u003e \u003cp\u003e4.6.5 Ratio of times to progression 81\u003c\/p\u003e \u003cp\u003e4.7 Randomised discontinuation designs 82\u003c\/p\u003e \u003cp\u003e4.7.1 Binary outcome measure 82\u003c\/p\u003e \u003cp\u003e4.7.2 Continuous outcome measure 82\u003c\/p\u003e \u003cp\u003e4.7.3 Multinomial outcome measure 82\u003c\/p\u003e \u003cp\u003e4.7.4 Time-to-event outcome measure 82\u003c\/p\u003e \u003cp\u003e4.7.5 Ratio of times to progression 82\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Treatment Selection Designs 83\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSarah Brown\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5.1 Including a control arm 84\u003c\/p\u003e \u003cp\u003e5.1.1 One-stage designs 84\u003c\/p\u003e \u003cp\u003e5.1.2 Two-stage designs 84\u003c\/p\u003e \u003cp\u003e5.1.3 Multi-stage designs 88\u003c\/p\u003e \u003cp\u003e5.1.4 Continuous monitoring designs 89\u003c\/p\u003e \u003cp\u003e5.1.5 Decision-theoretic designs 89\u003c\/p\u003e \u003cp\u003e5.1.6 Three-outcome designs 89\u003c\/p\u003e \u003cp\u003e5.1.7 Phase II\/III designs – same primary outcome measure at phase II and phase III 89\u003c\/p\u003e \u003cp\u003e5.1.8 Phase II\/III designs – different primary outcome measures at phase II and phase III 99\u003c\/p\u003e \u003cp\u003e5.1.9 Randomised discontinuation designs 102\u003c\/p\u003e \u003cp\u003e5.2 Not including a control arm 103\u003c\/p\u003e \u003cp\u003e5.2.1 One-stage designs 103\u003c\/p\u003e \u003cp\u003e5.2.2 Two-stage designs 106\u003c\/p\u003e \u003cp\u003e5.2.3 Multi-stage designs 108\u003c\/p\u003e \u003cp\u003e5.2.4 Continuous monitoring designs 109\u003c\/p\u003e \u003cp\u003e5.2.5 Decision-theoretic designs 110\u003c\/p\u003e \u003cp\u003e5.2.6 Three-outcome designs 110\u003c\/p\u003e \u003cp\u003e5.2.7 Phase II\/III designs – same primary outcome measure at phase II and phase III 110\u003c\/p\u003e \u003cp\u003e5.2.8 Randomised discontinuation designs 111\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Designs Incorporating Toxicity as a Primary Outcome 112\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSarah Brown\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6.1 Including a control arm 112\u003c\/p\u003e \u003cp\u003e6.1.1 One-stage designs 112\u003c\/p\u003e \u003cp\u003e6.1.2 Two-stage designs 114\u003c\/p\u003e \u003cp\u003e6.1.3 Multi-stage designs 115\u003c\/p\u003e \u003cp\u003e6.2 Not including a control arm 117\u003c\/p\u003e \u003cp\u003e6.2.1 One-stage designs 117\u003c\/p\u003e \u003cp\u003e6.2.2 Two-stage designs 118\u003c\/p\u003e \u003cp\u003e6.2.3 Multi-stage designs 122\u003c\/p\u003e \u003cp\u003e6.2.4 Continuous monitoring designs 125\u003c\/p\u003e \u003cp\u003e6.3 Toxicity alone 126\u003c\/p\u003e \u003cp\u003e6.3.1 One stage 126\u003c\/p\u003e \u003cp\u003e6.3.2 Continuous monitoring 127\u003c\/p\u003e \u003cp\u003e6.4 Treatment selection based on activity and toxicity 128\u003c\/p\u003e \u003cp\u003e6.4.1 Two-stage designs 128\u003c\/p\u003e \u003cp\u003e6.4.2 Multi-stage designs 129\u003c\/p\u003e \u003cp\u003e6.4.3 Continuous monitoring designs 129\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Designs Evaluating Targeted Subgroups 131\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSarah Brown\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7.1 One-stage designs 131\u003c\/p\u003e \u003cp\u003e7.1.1 Binary outcome measure 131\u003c\/p\u003e \u003cp\u003e7.2 Two-stage designs 132\u003c\/p\u003e \u003cp\u003e7.2.1 Binary outcome measure 132\u003c\/p\u003e \u003cp\u003e7.3 Multi-stage designs 135\u003c\/p\u003e \u003cp\u003e7.3.1 Binary outcome measure 135\u003c\/p\u003e \u003cp\u003e7.3.2 Time-to-event outcome measure 137\u003c\/p\u003e \u003cp\u003e7.4 Continuous monitoring designs 138\u003c\/p\u003e \u003cp\u003e7.4.1 Binary outcome measure 138\u003c\/p\u003e \u003cp\u003e7.4.2 Time-to-event outcome measure 139\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 ‘Chemo-radio-sensitisation’ in Head and Neck Cancer 141\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eJohn Chester and Sarah Brown\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eStage 1 – Trial questions 141\u003c\/p\u003e \u003cp\u003eTherapeutic considerations 141\u003c\/p\u003e \u003cp\u003ePrimary intention of trial 142\u003c\/p\u003e \u003cp\u003eNumber of experimental treatment arms 142\u003c\/p\u003e \u003cp\u003ePrimary outcome of interest 142\u003c\/p\u003e \u003cp\u003eStage 2 – Design components 142\u003c\/p\u003e \u003cp\u003eOutcome measure and distribution 142\u003c\/p\u003e \u003cp\u003eRandomisation 143\u003c\/p\u003e \u003cp\u003eDesign category 143\u003c\/p\u003e \u003cp\u003ePossible designs 144\u003c\/p\u003e \u003cp\u003eStage 3 – Practicalities 146\u003c\/p\u003e \u003cp\u003ePractical considerations for selecting between designs 146\u003c\/p\u003e \u003cp\u003eProposed trial design 148\u003c\/p\u003e \u003cp\u003eSummary 150\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Combination Chemotherapy in Second-line Treatment of Non-small Cell Lung Cancer 151\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eOrnella Belvedere and Sarah Brown\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eStage 1 – Trial questions 152\u003c\/p\u003e \u003cp\u003eTherapeutic considerations 152\u003c\/p\u003e \u003cp\u003ePrimary intention of trial 152\u003c\/p\u003e \u003cp\u003eNumber of experimental treatment arms 152\u003c\/p\u003e \u003cp\u003ePrimary outcome of interest 152\u003c\/p\u003e \u003cp\u003eStage 2 – Design components 153\u003c\/p\u003e \u003cp\u003eOutcome measure and distribution 153\u003c\/p\u003e \u003cp\u003eRandomisation 153\u003c\/p\u003e \u003cp\u003eDesign category 153\u003c\/p\u003e \u003cp\u003ePossible designs 154\u003c\/p\u003e \u003cp\u003eStage 3 – Practicalities 155\u003c\/p\u003e \u003cp\u003ePractical considerations for selecting between designs 155\u003c\/p\u003e \u003cp\u003eProposed trial design 158\u003c\/p\u003e \u003cp\u003eSummary 162\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Selection by Biomarker in Prostate Cancer 163\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eRick Kaplan and Sarah Brown\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eStage 1 – Trial questions 164\u003c\/p\u003e \u003cp\u003eTherapeutic considerations 164\u003c\/p\u003e \u003cp\u003ePrimary intention of trial 164\u003c\/p\u003e \u003cp\u003eNumber of experimental treatment arms 164\u003c\/p\u003e \u003cp\u003ePrimary outcome of interest 164\u003c\/p\u003e \u003cp\u003eStage 2 – Design components 165\u003c\/p\u003e \u003cp\u003eOutcome measure and distribution 165\u003c\/p\u003e \u003cp\u003eRandomisation 165\u003c\/p\u003e \u003cp\u003eDesign category 166\u003c\/p\u003e \u003cp\u003ePossible designs 167\u003c\/p\u003e \u003cp\u003eStage 3 – Practicalities 168\u003c\/p\u003e \u003cp\u003ePractical considerations for selecting between designs 168\u003c\/p\u003e \u003cp\u003eProposed trial design 170\u003c\/p\u003e \u003cp\u003eSummary 171\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 Dose Selection in Advanced Multiple Myeloma 174\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eSarah Brown and Steve Schey\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eStage 1 – Trial questions 174\u003c\/p\u003e \u003cp\u003eTherapeutic considerations 174\u003c\/p\u003e \u003cp\u003ePrimary intention of trial 175\u003c\/p\u003e \u003cp\u003eNumber of experimental arms 175\u003c\/p\u003e \u003cp\u003ePrimary outcome of interest 175\u003c\/p\u003e \u003cp\u003eStage 2 – Design components 176\u003c\/p\u003e \u003cp\u003eOutcome measure and distribution 176\u003c\/p\u003e \u003cp\u003eRandomisation 176\u003c\/p\u003e \u003cp\u003eDesign category 177\u003c\/p\u003e \u003cp\u003ePossible designs 177\u003c\/p\u003e \u003cp\u003eStage 3 – Practicalities 178\u003c\/p\u003e \u003cp\u003ePractical considerations for selecting between designs 178\u003c\/p\u003e \u003cp\u003eProposed trial design 181\u003c\/p\u003e \u003cp\u003eSummary 182\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Targeted Therapy for Advanced Colorectal Cancer 185\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMatthew Seymour and Sarah Brown\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eStage 1 – Trial questions 185\u003c\/p\u003e \u003cp\u003eTherapeutic considerations 185\u003c\/p\u003e \u003cp\u003ePrimary intention of trial 186\u003c\/p\u003e \u003cp\u003eNumber of experimental treatment arms 186\u003c\/p\u003e \u003cp\u003ePrimary outcome of interest 186\u003c\/p\u003e \u003cp\u003eStage 2 – Design components 187\u003c\/p\u003e \u003cp\u003eOutcome measure and distribution 187\u003c\/p\u003e \u003cp\u003eRandomisation 187\u003c\/p\u003e \u003cp\u003eDesign category 188\u003c\/p\u003e \u003cp\u003ePossible designs 189\u003c\/p\u003e \u003cp\u003eStage 3 – Practicalities 190\u003c\/p\u003e \u003cp\u003ePractical considerations for selecting between designs 190\u003c\/p\u003e \u003cp\u003eProposed trial design 191\u003c\/p\u003e \u003cp\u003eSummary 194\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Phase II Oncology Trials: Perspective from Industry 195\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAnthony Rossini, Steven Green and William Mietlowski\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13.1 Introduction 195\u003c\/p\u003e \u003cp\u003e13.2 Commercial challenges, drivers and considerations 196\u003c\/p\u003e \u003cp\u003e13.3 Selecting designs by strategy 197\u003c\/p\u003e \u003cp\u003e13.3.1 Basic strategies addressed by phase II studies 198\u003c\/p\u003e \u003cp\u003e13.3.2 Potential registration 198\u003c\/p\u003e \u003cp\u003e13.3.3 Exploratory activity 203\u003c\/p\u003e \u003cp\u003e13.3.4 Regimen selection 204\u003c\/p\u003e \u003cp\u003e13.3.5 Phase II to Support Predicting Success in Phase IIi 206\u003c\/p\u003e \u003cp\u003e13.3.6 Phase II safety trials 208\u003c\/p\u003e \u003cp\u003e13.3.7 Prospective identification of target populations 209\u003c\/p\u003e \u003cp\u003e13.4 Discussion 210\u003c\/p\u003e \u003cp\u003eReferences 213\u003c\/p\u003e \u003cp\u003eIndex 227 \u003c\/p\u003e \u003cb\u003eSarah Rose Brown\u003c\/b\u003e, \u003cb\u003eWalter M. Gregory\u003c\/b\u003e, \u003cb\u003eChristopher J. Twelves\u003c\/b\u003e, and \u003cb\u003eJulia M. Brown\u003c\/b\u003e, Clinical Trials Research Unit, University of Leeds, UK","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47988641956069,"sku":"NP9781118570906","price":72.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118570906.jpg?v=1761781084","url":"https:\/\/k12savings.com\/products\/a-practical-guide-to-designing-phase-ii-trials-in-oncology-isbn-9781118570906","provider":"K12savings","version":"1.0","type":"link"}